Article info
PDFClinical and epidemiological research
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
- Dr D van der Heijde, Department of Rheumatology, LUMC, PO Box 9600, 2300 RC Leiden, The Netherlands; d.vanderheijde{at}kpnplanet.nl
Citation
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
Publication history
- Accepted August 3, 2008
- First published August 13, 2008.
Online issue publication
April 04, 2023
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© van der Heijde et al 2009 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.